Skip to main content
Erschienen in: PharmacoEconomics 10/2003

01.07.2003 | Original Research Article

Lower Respiratory Tract Infections

Impact on the Workplace

verfasst von: Dr Howard G. Birnbaum, Melissa Morley, Stephanie Leong, Paul Greenberg, Gene L. Colice

Erschienen in: PharmacoEconomics | Ausgabe 10/2003

Einloggen, um Zugang zu erhalten

Abstract

Background: While there is some literature on the cost of specific respiratory infections, much of the existing research focuses only on direct medical treatment costs and does not take into consideration workplace burden due to disability and absenteeism.
Objective: To evaluate the impact of lower respiratory tract infections (LRTIs) on the workplace, specifically regarding the economic burden from an employer’s perspective.
Design: Specific LRTI considered here were acute bronchitis, acute exacerbations of chronic bronchitis and pneumonia. Data from medical, prescription drug and disability claims of a large, national company in the US were used. These data provide information on both the healthcare and work loss impacts of LRTI on this major self-insured employer. The annual per capita expenditures for persons with LRTI were determined for beneficiaries (including employees and dependants) of this employer by analysing all claims in 1997. Results were compared with those of a 10% random sample of beneficiaries in the employer’s overall beneficiary population.
Results: In 1997, total per person expenditures and total medical service utilisation were higher among beneficiaries with LRTI than among beneficiaries in the overall beneficiary population sample. Annual per capita employer expenditures for beneficiaries with LRTI totalled $US6116, compared with $US2368 (1997 values) for the average beneficiary in the overall beneficiary population sample. Employer payments for lost work time through disability and absenteeism accounted for 17% of these expenditures amongst beneficiaries with LRTI and for 35% amongst employees with LRTI.
Conclusions: Annual per capita expenditures for beneficiaries with LRTI were almost three times that of the average beneficiary. We conclude that it is important to consider work loss in analyses of the cost of LRTI.
Literatur
1.
Zurück zum Zitat Snow V, Mottur-Pilson C, Gonzales R, et al. Principles of appropriate antibiotic use for treatment of acute bronchitis in adults. Ann Intern Med 2001 Mar 20; 134 (6): 518–20PubMed Snow V, Mottur-Pilson C, Gonzales R, et al. Principles of appropriate antibiotic use for treatment of acute bronchitis in adults. Ann Intern Med 2001 Mar 20; 134 (6): 518–20PubMed
2.
Zurück zum Zitat Snow V, Lascher S, Mottur-Pilson C, et al. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001 Apr 3; 134 (7): 595–9PubMed Snow V, Lascher S, Mottur-Pilson C, et al. Evidence base for management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001 Apr 3; 134 (7): 595–9PubMed
3.
Zurück zum Zitat Bach PB, Brown C, Gelfand SE, et al. Management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001 Apr 3; 134 (7): 600–20PubMed Bach PB, Brown C, Gelfand SE, et al. Management of acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2001 Apr 3; 134 (7): 600–20PubMed
4.
Zurück zum Zitat Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch Intern Med 2000 May 22; 160 (10): 1399–408PubMedCrossRef Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch Intern Med 2000 May 22; 160 (10): 1399–408PubMedCrossRef
5.
Zurück zum Zitat Kollef M. The prevention of ventilator-associated pneumonia. N Engl J Med 1999 Feb 25; 340 (8): 627–34PubMedCrossRef Kollef M. The prevention of ventilator-associated pneumonia. N Engl J Med 1999 Feb 25; 340 (8): 627–34PubMedCrossRef
6.
Zurück zum Zitat Macfarlane IT, Colville A, Guion A, et al. Prospective study of aetiology and outcome of adult lower respiratory tract infections in the community. Lancet 1993 Feb 27; 341 (8844): 511–4CrossRef Macfarlane IT, Colville A, Guion A, et al. Prospective study of aetiology and outcome of adult lower respiratory tract infections in the community. Lancet 1993 Feb 27; 341 (8844): 511–4CrossRef
8.
Zurück zum Zitat Vital and health statistics: current estimates from the National Health review survey, 1996. Series 10, No. 200. Washington, D.C.: Centers for Disease Control and Prevention National Center for Health Statistics, 1999 Oct Vital and health statistics: current estimates from the National Health review survey, 1996. Series 10, No. 200. Washington, D.C.: Centers for Disease Control and Prevention National Center for Health Statistics, 1999 Oct
10.
Zurück zum Zitat Georges H, Leroy O, Vandenbussche C, et al. Epidemiological features and prognosis of severe community-acquired pneumoccocal respiratory infection. Intensive Care Med 1999 Feb; 25 (2): 198–206PubMedCrossRef Georges H, Leroy O, Vandenbussche C, et al. Epidemiological features and prognosis of severe community-acquired pneumoccocal respiratory infection. Intensive Care Med 1999 Feb; 25 (2): 198–206PubMedCrossRef
11.
Zurück zum Zitat Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000 May; 117 (5 Suppl. 2): 380S–5SPubMedCrossRef Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. Chest 2000 May; 117 (5 Suppl. 2): 380S–5SPubMedCrossRef
12.
Zurück zum Zitat White CB, Foshee WS. Upper respiratory tract infections in adolescents. Adolesc Med 2000 Jun; 11 (2): 225–49PubMed White CB, Foshee WS. Upper respiratory tract infections in adolescents. Adolesc Med 2000 Jun; 11 (2): 225–49PubMed
13.
Zurück zum Zitat Niederman MS, McCombs IS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998 Jul–Aug; 20 (4): 820–37PubMedCrossRef Niederman MS, McCombs IS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998 Jul–Aug; 20 (4): 820–37PubMedCrossRef
14.
Zurück zum Zitat Niederman MS, McCombs IS, Unger AN, et al. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther 1999 Mar; 21 (3): 576–91PubMedCrossRef Niederman MS, McCombs IS, Unger AN, et al. Treatment cost of acute exacerbations of chronic bronchitis. Clin Ther 1999 Mar; 21 (3): 576–91PubMedCrossRef
15.
Zurück zum Zitat McGuire A, Irwin DE, Fenn P, et al. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value Health 2001 Sep–Oct; 4 (5): 370–5PubMedCrossRef McGuire A, Irwin DE, Fenn P, et al. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales. Value Health 2001 Sep–Oct; 4 (5): 370–5PubMedCrossRef
16.
Zurück zum Zitat Wilson L, Devine EB, So K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med 2000 Mar; 94 (3): 204–13PubMedCrossRef Wilson L, Devine EB, So K. Direct medical costs of chronic obstructive pulmonary disease: chronic bronchitis and emphysema. Respir Med 2000 Mar; 94 (3): 204–13PubMedCrossRef
17.
Zurück zum Zitat Ward MM, Javitz HS, Smith WM, et al. Direct medical costs of chronic obstructive pulmonary disease in USA. Respir Med 2000 Nov; 94 (11): 1123–9PubMedCrossRef Ward MM, Javitz HS, Smith WM, et al. Direct medical costs of chronic obstructive pulmonary disease in USA. Respir Med 2000 Nov; 94 (11): 1123–9PubMedCrossRef
18.
Zurück zum Zitat Rutten van-Molken MP, Feenstra TL. The burden of asthma and chronic obstructive pulmonary disease: data from The Netherlands. Pharmacoeconomics 2001; 19 Suppl. 2: 1–6CrossRef Rutten van-Molken MP, Feenstra TL. The burden of asthma and chronic obstructive pulmonary disease: data from The Netherlands. Pharmacoeconomics 2001; 19 Suppl. 2: 1–6CrossRef
19.
Zurück zum Zitat Garrelts JC, Herrington AM. Cost-effective treatment of lower respiratory tract infections. Pharmacoeconomics 1996 Jul; 10 (1): 36–58PubMedCrossRef Garrelts JC, Herrington AM. Cost-effective treatment of lower respiratory tract infections. Pharmacoeconomics 1996 Jul; 10 (1): 36–58PubMedCrossRef
20.
Zurück zum Zitat Plosker GL, Foster RH, Benfield P. Cefotaxime: a pharmacoeconomic review of its use in the treatment of infections. Pharmacoeconomics 1998 Jan; 13 (1 Pt 1): 91–106PubMedCrossRef Plosker GL, Foster RH, Benfield P. Cefotaxime: a pharmacoeconomic review of its use in the treatment of infections. Pharmacoeconomics 1998 Jan; 13 (1 Pt 1): 91–106PubMedCrossRef
21.
Zurück zum Zitat Grossman R. Cost-effective therapy for acute exacerbations of chronic bronchitis. Semin Respir Infect 2000; 15 (1): 71–81PubMedCrossRef Grossman R. Cost-effective therapy for acute exacerbations of chronic bronchitis. Semin Respir Infect 2000; 15 (1): 71–81PubMedCrossRef
22.
Zurück zum Zitat Li-McLeod J, Perfetto EM. Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin. Manag Care Interface 2001 Feb; 14 (2): 52–9PubMed Li-McLeod J, Perfetto EM. Workplace costs associated with acute exacerbation of chronic bronchitis: a comparison of moxifloxacin and levofloxacin. Manag Care Interface 2001 Feb; 14 (2): 52–9PubMed
23.
Zurück zum Zitat Grossman RF. How do we achieve cost-effective options in lower respiratory tract infection therapy? Chest 1998 Mar; 113 (3 Suppl.): 205S–10SPubMedCrossRef Grossman RF. How do we achieve cost-effective options in lower respiratory tract infection therapy? Chest 1998 Mar; 113 (3 Suppl.): 205S–10SPubMedCrossRef
24.
Zurück zum Zitat Birnbaum HG, Cremieux PY, Greenberg PE, et al. Using healthcare claims data for outcomes research and pharmacoeconomic analyses. Pharmacoeconomics 1999 Jul; 16 (1): 1–8PubMedCrossRef Birnbaum HG, Cremieux PY, Greenberg PE, et al. Using healthcare claims data for outcomes research and pharmacoeconomic analyses. Pharmacoeconomics 1999 Jul; 16 (1): 1–8PubMedCrossRef
25.
Zurück zum Zitat Burton WN, Conti DJ. Use of an integrated health data warehouse to measure the employer cots of five chronic disease states. Dis Manag Health Outcomes 1998; 2 (1): 17–26 Burton WN, Conti DJ. Use of an integrated health data warehouse to measure the employer cots of five chronic disease states. Dis Manag Health Outcomes 1998; 2 (1): 17–26
26.
Zurück zum Zitat Barnett A, Birnbaum HG, Cremieux PY, et al. The costs of cancer to a major employer in the United States: a case-control analysis. Am J Manag Care 2000 Nov; 6 (11): 1243–51PubMed Barnett A, Birnbaum HG, Cremieux PY, et al. The costs of cancer to a major employer in the United States: a case-control analysis. Am J Manag Care 2000 Nov; 6 (11): 1243–51PubMed
29.
Zurück zum Zitat Birnbaum H, Morley M, Greenberg PE, et al. Economic burden of pneumonia in an employed population. Arch Intern Med 2001 Dec 10–24; 161 (22): 2725–31PubMedCrossRef Birnbaum H, Morley M, Greenberg PE, et al. Economic burden of pneumonia in an employed population. Arch Intern Med 2001 Dec 10–24; 161 (22): 2725–31PubMedCrossRef
30.
Zurück zum Zitat Destache CJ. Optimizing economic outcomes in acute exacerbations of chronic bronchitis. Pharmacotherapy 2002 Jan; 22 (1 Pt 2): 12S–7SPubMedCrossRef Destache CJ. Optimizing economic outcomes in acute exacerbations of chronic bronchitis. Pharmacotherapy 2002 Jan; 22 (1 Pt 2): 12S–7SPubMedCrossRef
Metadaten
Titel
Lower Respiratory Tract Infections
Impact on the Workplace
verfasst von
Dr Howard G. Birnbaum
Melissa Morley
Stephanie Leong
Paul Greenberg
Gene L. Colice
Publikationsdatum
01.07.2003
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 10/2003
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200321100-00006

Weitere Artikel der Ausgabe 10/2003

PharmacoEconomics 10/2003 Zur Ausgabe